Growth Hormone Therapy in Adults

Conceição, Flávia Lúcia; Bojensen, Anders; Jørgensen, Jens Otto Lunde; Christiansen, Jens Sandahl

doi:10.1006/frne.2001.0215

Cited by 17 publications

(9 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In animals, hypoxia inhibits growth hormone release or biosynthesis [90]. Growth hormone deficiency in adults is associated with impaired psychological well-being, insulin resistance, endothelial dysfunction, increased visceral fat, increased cardiovascular mortality and accelerated ageing [91,92]. Similar features are typical in OSAS, which raises the question of a possible link between OSAS-related growth hormone deficiency and the comorbidity seen in OSAS.…”

Section: Growth Hormone Deficiencymentioning

confidence: 99%

Sleep-disordered breathing and hormones

Saaresranta¹,

Polo²

2003

Eur Respir J

View full text Add to dashboard Cite

Sleep-disordered breathing (SDB) is not only a problem of the upper airway but is a systemic condition with endocrine and metabolic interactions. The accumulating body of evidence shows that SDB induces changes in the serum levels or secretory patterns of several hormones. Conversely, various endocrine disorders and hormone therapies may induce, exacerbate or alleviate SDB.Much of the understanding of the interactions between hormones and sleepdisordered breathing derive from intervention studies with nasal continuous positive airway pressure therapy. Better understanding of hormones and breathing may open new perspectives in developing strategies to prevent, alleviate or cure sleep-disordered breathing and its systemic consequences. Eur Respir J 2003; 22: 161-172.

show abstract

Section: Growth Hormone Deficiencymentioning

confidence: 99%

Sleep-disordered breathing and hormones

Saaresranta¹,

Polo²

2003

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Numerous reviews have described the diversity of effects of GH replacement therapy (e.g. [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Circulating IGF-I levels in monitoring and predicting efficacy during long-term GH treatment of GH-deficient adults

Ezzat

Fear²,

Rc³

et al. 2003

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To investigate the effects of long-term GH in GH-deficient adults, as predicted by IGF-I levels. Methods: Patients received GH, 5 mg/kg per day for 1 month and 10 mg/kg per day for another 12-30 months. Changes in body composition, cardiac structure/function, serum lipids and quality of life were measured. Results: There was a significant increase in lean body mass (LBM) (2.21 kg; P , 0.0001) after 6 months, which was sustained throughout treatment. A larger increase occurred in males than females (2.97 vs 1.19 kg; P , 0.0001). Total fat mass was reduced (2.56 kg; P , 0.0001 (3.26 kg males, 1.63 kg females)). Responsiveness to GH varied greatly, but LBM changes correlated with IGF-I changes (P , 0.004). Furthermore, thinner patients experienced greater and progressive LBM increases. There was an increase in ejection fraction (3.85^9.95%; P ¼ 0.0002) after 6 months, sustained to 18 months. These cardiac effects were equal for males and females, and did not correlate with IGF-I levels. Serum low-density lipoprotein/high-density lipoprotein ratios decreased within 6 months, and were sustained thereafter. Quality of life improved significantly after 6 months, an effect that was sustained/enhanced as treatment continued. No major adverse events were identified. Conclusions: Improved body composition is both reflected by IGF-I changes and predicted inversely by baseline adiposity. Other effects of GH replacement on cardiac function, dyslipidaemia and quality of life, however, do not correlate with circulating IGF-I concentrations. Our findings validate the importance of sustained GH therapy, but caution on the interpretation of IGF-I levels in monitoring the longterm effects of GH treatment.

show abstract

“…Despite the long list of clinical features that constitute the adult GHD syndrome, no specific clinical parameters have been identified (19)(20)(21). As a result, the endocrinologists must rely on the pharmacological stimulation of the pituitary somatotroph to establish the diagnosis of GHD.…”

Section: Discussionmentioning

confidence: 99%

Growth hormone secretion in response to glucagon stimulation test in healthy middle-aged men

Micmacher

Assumpção

Redorat

et al. 2009

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: To investigate the growth hormone (GH) response to glucagon stimulation test (GST) in a population of healthy men over 50 years old in comparison to insulin tolerance test (ITT), analysis of the spontaneous 24-hour GH profile and insulin-like growth factor 1 (IGF-I). Me thods: 27 healthy men aged between 51 and 65 years were tested. Results: Using non-parametric correlation analysis, a positive correlation between GH peak after GST and mean IGF-I (r = 0.528; p = 0.005) was found, as well with GH peak in 24-hour profile (r = 0.494; p = 0.009). No correlation was found comparing GH peak after ITT with the same parameters. Ten subjects presented GH peak of less than 3.0 μg/L after GST, none confirmed in ITT. Conclusions: GH peak response to GST was lower than ITT, but it showed a positive correlation with mean IGF-I and also with GH peak in 24-hour profile. However, GST should not be used to differentiate organic growth hormone deficiency (GDH) from the expected decline on GH secretion due to aging. Arq Bras Endocrinol Metab. 2009;53(7):853-8. KeywordsGrowth hormone; somatopause; glucagon RESUMO Objetivo: Investigar a resposta do hormônio do crescimento (GH) ao teste de estímulo com glucagon (GST) numa população de homens saudáveis acima dos 50 anos de idade, em comparação ao teste de tolerância à insulina (ITT), além da análise do perfil de secreção espontânea de GH nas 24 horas e fator de crescimento semelhante à insulina (IGF-I) basal. Métodos: 27 homens, com idades entre 51 e 65 anos, foram submetidos aos testes. Resultados: Utilizando análise de correlação não paramétrica, encontrou-se correlação positiva entre o pico de GH pós-GST e a média de IGF-I (r = 0,528; p = 0,005), e também com o pico espontâneo do GH no perfil de 24 horas (r = 0,494; p = 0,009). Não houve correlação do pico de GH pós-ITT com os mesmos parâmetros. Dez indivíduos apresentaram pico de GH após GST inferior a 3,0 μg/L, sem confirmação no ITT. Conclusões: O pico de GH pós-GST foi menor do que o obtido pós-ITT, porém demonstrou correlação positiva com a média de IGF-I e o pico de GH na secreção espontânea de 24 horas. Entretanto, o GST não demonstrou ser um bom teste para distinguir entre deficiência de hormônio de crescimento (DGH) e somatopausa. Arq Bras Endocrinol Metab. 2009;53(7):853-8. DescritoresHormônio do crescimento; somatopausa; glucagon

show abstract

Growth Hormone Therapy in Adults

Cited by 17 publications

References 113 publications

Sleep-disordered breathing and hormones

Sleep-disordered breathing and hormones

Circulating IGF-I levels in monitoring and predicting efficacy during long-term GH treatment of GH-deficient adults

Growth hormone secretion in response to glucagon stimulation test in healthy middle-aged men

Contact Info

Product

Resources

About